Skip to main content
OpenTrials
Completed

NCT Number: NCT02472795

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erythematosus Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Lupus Erythematosus, Systemic Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Investigator Site, Minsk, Belarus

Loading trial locations.

About this study

This multicentre, double-blind, placebo-controlled study will have a staggered approach (Part A and B).

In part A, eligible patients will be randomly assigned (1:1:1:1) to once daily oral administration of cenerimod (0.5, 1, 2 mg) or placebo. After all patients have completed 4 weeks of treatment during part A, an Independent Data Monitoring Committee will review non-blinded data in an interim analysis to evaluate the safety profile of cenerimod and recommend whether the study could proceed to part B.

In part B, additional patients will be randomized (3:1) to once daily oral administration of cenerimod 4 mg or placebo.

All participants will receive study medication for 12 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female participants aged 18 to 65 years with established SLE. Participants must have active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at screening of positive anti-nuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.
  • Enrolled participants must be treated with background SLE medications.

Exclusion criteria

  • Participants with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of malignancy, history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women.
  • Participants with severe SLE disease or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.

Treatment and study plan

Matching Placebo

Drug

One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Other names: Placebo

Cenerimod

Drug

One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Other names: ACT-334441

Primary outcomes

  1. Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)

    Time frame: Baseline to end-of-treatment (EOT) (up to 12 weeks)

    The primary objective of the clinical study was to asses whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE).

    The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline.

    A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased.

    The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect.

    The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake.

    End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

  2. Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)

    The primary objective of the clinical study was to assess whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE).

    The change was defined as: Total lymphocyte count at visit minus total lymphocyte count at baseline.

    A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased.

    The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect.

    The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake.

    End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

Sponsors and collaborators

Lead sponsor

Viatris Innovation GmbH

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jun 16, 2015
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.